Changes in Hong Kong stocks | Jietai Technology-P (07666) rose more than 9%, multiple resonances drive the value of AI+ delivery platforms for AI pharmaceutical upward companies to gradually show

The Zhitong Finance App learned that Jetai Technology-P (07666) has risen by more than 9% and has risen more than 35% in the past three trading days. As of press release, it rose 7.18% to HK$18.65, with a turnover of HK$115 million.

According to the news, on September 18, 10 departments including the Ministry of Industry and Information Technology jointly issued the “15th Five-Year Plan for the Development of the Pharmaceutical Industry”. This programmatic document includes AI pharmaceuticals as a key task in the five-year plan for the pharmaceutical industry, clearly proposes “deepening the upgrading of artificial intelligence capabilities”, and specifically lists the “Cultivating High-Value Application Scenarios for AI Pharmaceuticals” column. Currently, AI pharmaceuticals are on the upward channel of additional capital from outside the industry and two-wheel drive within the industry's R&D budget. Within the industry, MNCs such as Eli Lilly continue to expand the application of AI in drug discovery, pre-clinical, and R&D processes; Anthropic has set up biological laboratories to promote AI drug development projects.

Previously, the world's first clinically proven mRNA-therapeutic cancer vaccine confirmed the viability and commercialization value of mRNA technology for cancer treatment. In this context, the Jietai Technology NanoForge platform has been recognized by the secondary market for its mRNA tumor vaccine research and development capability+LNP delivery capability. It is worth mentioning that the company's platform cooperation and product licensing are two-wheel drive, and OpenCGT has further opened up AiLNP capabilities to cell and gene therapy partners. The total potential transaction amount for related cooperation exceeds RMB 6 billion.